Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.

doi:10.1158/1078-0432.CCR-22-1696

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.

Clinical cancer research : an official journal of the American Association for Cancer Research - 17 Jan 2023

Vidal Joana, Fernández-Rodríguez Maria Concepción, Casadevall David, García-Alfonso Pilar, Páez David, Guix Marta, Alonso Vicente, Cano Maria Teresa, Santos Cristina, Durán Gema, Elez Elena, Manzano José Luís, Garcia-Carbonero Rocío, Ferreiro Reyes, Losa Ferran, Pineda Estela, Sastre Javier, Rivera Fernando, Bellosillo Beatriz, Tabernero Josep, Aranda Enrique, Salazar Ramon, Montagut Clara

Abstract excerpt

PURPOSE: Chemotherapy plus anti-EGFR is standard first-line therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC), but biomarkers of early response are clinically needed. We aimed to define the utility of ctDNA to assess early response in patients with mCRC receiving first-line anti-EGFR therapy. EXPERIMENTAL DESIGN: Prospective multicentric study of tissue patients with RAS wt mCRC treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colonic Neoplasms

Share to Colorectal Neoplasms

Share to Liquid Biopsy

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Rectal Neoplasms

Source

Open in PubMed

Identifiers

PMID: 36074154
DOI: 10.1158/1078-0432.CCR-22-1696

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.PMID 36074154Read ↗

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.Semantic proximity Read ↗

Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial.Semantic proximity Read ↗

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.Semantic proximity Read ↗

Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.Semantic proximity Read ↗

Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot studySemantic proximity Read ↗

Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic ResponseSemantic proximity Read ↗

Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.Semantic proximity Read ↗

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancerSemantic proximity Read ↗

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.Semantic proximity Read ↗

Circulating tumour DNA-guided second-line targeted therapy for patients with metastatic colorectal cancer after failure of first-line cetuximab-based treatment: A prospective, phase II trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.